Hormone replacement therapy safe, may be beneficial for women treated for ovarian cancer

the ONA take:

Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy (HRT); furthermore, HRT can have a beneficial effect on their survival, according to a 24-year, phase III international trial.

Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust led the trial, which is the largest trial to investigate HRT’s effects on ovarian cancer survival.

The trial was set up in 1990 and followed 150 women with epithelial ovarian cancer. Half of the women were allocated to receive HRT during their treatment for up to 5 years, and half did not receive HRT. Overall survival in the two groups was compared at a point in 2012, 22 years after the trial began.

In the HRT arm of the trial, 53 of the 75 women (71%) had died, compared with 68 of the 75 women (91%) who had not taken HRT.

The researchers report these results are relevant to a large proportion of women with ovarian cancer because its treatment can trigger menopause.

“We were really happy to be able to show that HRT is safe for women with the most common type of ovarian cancer. Whether or not to have HRT is a very important decision for a large proportion of women with ovarian cancer, who will often have to undergo the menopause due to the cancer treatment at the same time as coping with a cancer diagnosis,” said study clinical lead Professor Ros Eeles, professor of Oncogenetics at The Institute of Cancer Research, London, and consultant at The Royal Marsden NHS Foundation Trust.

Hormone replacement therapy safe, may be beneficial for women treated for ovarian cancer
Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy.
Women with the commonest type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival, a long-term clinical trial reports. The 24-year, phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer - which accounts for 80-90 per cent of cases - can safely take HRT during or after their treatment.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs